Literature DB >> 26962053

Iron and dopamine: a toxic couple.

Dominic J Hare, Kay L Double.   

Abstract

Iron accumulation is a cardinal feature of degenerating regions in the Parkinson's disease brain. As a potent pro-oxidant, redox-active iron may be a key player in upstream mechanisms that precipitate cell death in this disorder. Although an elevation in brain iron levels is a normal feature of ageing, the increase is greater in Parkinson's disease; on the other hand, the effects of the disease are most marked in the nigrostriatal dopaminergic system. In this Update, we explain that neurodegeneration in the affected regions may result from the potent redox couple formed by iron and dopamine itself, and discuss the clinical implications of this molecular trait in this dynamic and rapidly moving area of Parkinson's disease research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26962053     DOI: 10.1093/brain/aww022

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  69 in total

1.  Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Authors:  Niels Bergsland; Eleonora Tavazzi; Ferdinand Schweser; Dejan Jakimovski; Jesper Hagemeier; Michael G Dwyer; Robert Zivadinov
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

2.  Mitoferrin-1 is required for brain energy metabolism and hippocampus-dependent memory.

Authors:  Lisa Baldauf; Thomas Endres; Johannes Scholz; Elmar Kirches; Diane M Ward; Volkmar Lessmann; Katrin Borucki; Christian Mawrin
Journal:  Neurosci Lett       Date:  2019-09-26       Impact factor: 3.046

3.  Extracellular α-Synuclein Modulates Iron Metabolism Related Proteins via Endoplasmic Reticulum Stress in MES23.5 Dopaminergic Cells.

Authors:  Xiaoqing Mi; Qijun Li; Xiaoming Wen; Junxia Xie; Youcui Wang; Ning Song
Journal:  Neurochem Res       Date:  2021-03-11       Impact factor: 3.996

4.  Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain.

Authors:  Sian Genoud; Blaine R Roberts; Adam P Gunn; Glenda M Halliday; Simon J G Lewis; Helen J Ball; Dominic J Hare; Kay L Double
Journal:  Metallomics       Date:  2017-10-18       Impact factor: 4.526

Review 5.  Interrogating Parkinson's disease associated redox targets: Potential application of CRISPR editing.

Authors:  M A Artyukhova; Y Y Tyurina; C T Chu; T M Zharikova; H Bayır; V E Kagan; P S Timashev
Journal:  Free Radic Biol Med       Date:  2019-06-12       Impact factor: 7.376

6.  Iron, Dopamine, and α-Synuclein Interactions in at-Risk Dopaminergic Neurons in Parkinson's Disease.

Authors:  Ning Song; Junxia Xie
Journal:  Neurosci Bull       Date:  2018-01-29       Impact factor: 5.203

Review 7.  Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective.

Authors:  Paul J Derry; Muralidhar L Hegde; George R Jackson; Rakez Kayed; James M Tour; Ah-Lim Tsai; Thomas A Kent
Journal:  Prog Neurobiol       Date:  2019-10-08       Impact factor: 11.685

Review 8.  Glutathione peroxidase 4: a new player in neurodegeneration?

Authors:  B R Cardoso; D J Hare; A I Bush; B R Roberts
Journal:  Mol Psychiatry       Date:  2016-10-25       Impact factor: 15.992

Review 9.  Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  David Devos; Z Ioav Cabantchik; Caroline Moreau; Véronique Danel; Laura Mahoney-Sanchez; Hind Bouchaoui; Flore Gouel; Anne-Sophie Rolland; James A Duce; Jean-Christophe Devedjian
Journal:  J Neural Transm (Vienna)       Date:  2020-01-07       Impact factor: 3.575

Review 10.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.